Sign Up Today and Learn More About Astrocyte Pharmaceuticals Stock
Invest in or calculate the value of your shares in Astrocyte Pharmaceuticals or other pre-IPO companies through EquityZen, part of Morgan Stanley.
Astrocyte Pharmaceuticals Stock (ASPH)
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients.
About Astrocyte Pharmaceuticals Stock
Founded
2014
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Astrocyte Pharmaceuticals Press Mentions
Stay in the know about the latest news on Astrocyte Pharmaceuticals
OMRF scientist to study potential treatment for meth, cocaine addiction
journalrecord • Aug 26, 2026
Astrocyte Pharmaceuticals Receives NIH Award to Evaluate AST-004 in Substance Use Disorders
biospace • Aug 25, 2026
Compounds and methods for treating neurological and cardiovascular conditions
patents • Mar 01, 2026
Compounds and methods for treating neurological and cardiovascular conditions
patents • Mar 01, 2026
Compositions for intravenous administration
patents • Feb 09, 2025
Astrocyte Pharmaceuticals Management
Leadership team at Astrocyte Pharmaceuticals
Co-Founder and Chief Executive Officer
William Korinek
Co-Founder
James Lechleiter
Join now and verify your accreditation status to gain access to:
- Astrocyte Pharmaceuticals Current Valuation
- Astrocyte Pharmaceuticals Stock Price
- Astrocyte Pharmaceuticals Management
- Available deals in Astrocyte Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Astrocyte Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Astrocyte Pharmaceuticals Revenue and Financials
- Astrocyte Pharmaceuticals Highlights
- Astrocyte Pharmaceuticals Business Model
- Astrocyte Pharmaceuticals Risk Factors
- Astrocyte Pharmaceuticals Research Report from SACRA Research
Trading Astrocyte Pharmaceuticals Stock
How to invest in Astrocyte Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Astrocyte Pharmaceuticals through EquityZen funds. These investments are made available by existing Astrocyte Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Astrocyte Pharmaceuticals stock?
Shareholders can sell their Astrocyte Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 480K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 56K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
